Tenet Healthcare Corporation (NYSE:THC) Receives Consensus Rating of "Moderate Buy" from Analysts

Key Points

• Analysts remain bullish: Tenet Healthcare has a “Moderate Buy” consensus from 21 analysts, with 18 buys, two holds and one strong buy. The average 12-month price target is $273, slightly above the stock’s $267.23 opening price.
• Quarterly results exceeded expectations: Tenet reported adjusted EPS of $6.12 versus the $4.26 consensus and revenue of $6.04 billion versus $5.43 billion expected. Revenue increased 6.8% year over year, and analysts expect approximately $20.97 in full-year EPS.
• Insiders have been selling while institutions remain heavily invested: Company insiders sold $9.8 million of stock over the past three months, while institutional investors and hedge funds own 95.44% of Tenet’s shares.

Shares of Tenet Healthcare Corporation (NYSE:THC - Get Free Report) have been assigned an average rating of "Moderate Buy" from the twenty-one analysts that are covering the firm, MarketBeat reports. Two investment analysts have rated the stock with a hold recommendation, eighteen have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $273.00.

A number of equities analysts have recently commented on THC shares. Raymond James Financial reissued an "outperform" rating and set a $285.00 price objective on shares of Tenet Healthcare in a research report on Friday. Guggenheim boosted their price target on shares of Tenet Healthcare from $242.00 to $283.00 and gave the stock a "buy" rating in a report on Tuesday, July 28th. The Goldman Sachs Group restated a "buy" rating and issued a $305.00 price objective on shares of Tenet Healthcare in a report on Tuesday, July 28th. TD Cowen increased their target price on Tenet Healthcare from $233.00 to $263.00 and gave the company a "buy" rating in a report on Monday, July 27th. Finally, Piper Sandler set a $308.00 price objective on Tenet Healthcare in a research report on Monday, July 27th.

Tenet Healthcare Stock Down 0.3%

Tenet Healthcare stock opened at $267.23 on Monday. The firm has a market capitalization of $21.52 billion, a P/E ratio of 10.31, a P/E/G ratio of 1.02 and a beta of 1.23. The company has a current ratio of 1.41, a quick ratio of 1.35 and a debt-to-equity ratio of 2.00. Tenet Healthcare has a twelve month low of $157.58 and a twelve month high of $270.57. The stock's fifty day simple moving average is $210.20 and its 200-day simple moving average is $204.03.

Tenet Healthcare (NYSE:THC - Get Free Report) last released its earnings results on Thursday, July 23rd. The company reported $6.12 EPS for the quarter, topping the consensus estimate of $4.26 by $1.86. The firm had revenue of $6.04 billion during the quarter, compared to analysts' expectations of $5.43 billion. Tenet Healthcare had a return on equity of 26.76% and a net margin of 10.27%.Tenet Healthcare's revenue for the quarter was up 6.8% on a year-over-year basis. During the same period in the previous year, the firm posted $4.02 EPS. Tenet Healthcare has set its FY 2026 guidance at 20.300-21.690 EPS. As a group, equities analysts expect that Tenet Healthcare will post 20.97 earnings per share for the current fiscal year.

Insider Transactions at Tenet Healthcare

In related news, Director J Robert Kerrey sold 5,638 shares of the firm's stock in a transaction that occurred on Thursday, May 28th. The stock was sold at an average price of $174.52, for a total transaction of $983,943.76. Following the transaction, the director owned 16,804 shares in the company, valued at $2,932,634.08. This trade represents a 25.12% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Christopher S. Lynch sold 3,837 shares of Tenet Healthcare stock in a transaction on Monday, July 27th. The shares were sold at an average price of $243.44, for a total transaction of $934,079.28. Following the completion of the transaction, the director directly owned 9,568 shares in the company, valued at $2,329,233.92. The trade was a 28.62% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 41,375 shares of company stock valued at $9,793,347 over the last three months. 0.97% of the stock is owned by corporate insiders.

Institutional Trading of Tenet Healthcare

A number of hedge funds have recently added to or reduced their stakes in THC. Price T Rowe Associates Inc. MD increased its holdings in shares of Tenet Healthcare by 1.6% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 7,490,350 shares of the company's stock valued at $1,488,484,000 after purchasing an additional 119,809 shares during the period. Boston Partners lifted its holdings in shares of Tenet Healthcare by 15.7% during the fourth quarter. Boston Partners now owns 3,642,136 shares of the company's stock worth $723,804,000 after purchasing an additional 494,581 shares during the period. AQR Capital Management LLC grew its position in Tenet Healthcare by 20.3% in the 4th quarter. AQR Capital Management LLC now owns 2,256,539 shares of the company's stock valued at $448,419,000 after buying an additional 380,116 shares during the last quarter. Ameriprise Financial Inc. increased its stake in Tenet Healthcare by 8.0% in the 2nd quarter. Ameriprise Financial Inc. now owns 2,119,423 shares of the company's stock valued at $373,020,000 after buying an additional 157,109 shares during the period. Finally, Norges Bank purchased a new position in Tenet Healthcare during the 4th quarter worth $248,494,000. 95.44% of the stock is owned by institutional investors and hedge funds.

Trending Headlines about Tenet Healthcare

Here are the key news stories impacting Tenet Healthcare this week:

• Positive Sentiment: An analyst boosted Tenet’s third-quarter EPS forecast, signaling improving expectations for the company’s near-term profitability. Q3 EPS Forecast for Tenet Healthcare Boosted by Analyst
• Positive Sentiment: Zacks Research raised its Tenet EPS estimates across multiple periods: fourth-quarter 2026 EPS increased to $5.04 from $4.47, fiscal 2026 EPS to $20.32 from $17.52, fiscal 2027 EPS to $18.91 from $17.17, and fiscal 2028 EPS to $20.09 from $17.99. Quarterly estimates for Q2 2027, Q3 2027, Q4 2027 and Q2 2028 were also increased. Zacks maintained a “Strong-Buy” rating, supporting the bullish outlook for earnings growth.
• Neutral Sentiment: The revised fiscal 2026 estimate of $20.32 remains below the broader analyst consensus of $21.07, suggesting that Zacks’ revisions are favorable but do not represent an across-the-board increase in expectations.
• Neutral Sentiment: Wall Street Zen downgraded Tenet from “Strong Buy” to “Buy.” Although the stock remains positively rated, the change reflects somewhat less conviction and could limit the impact of the otherwise favorable earnings revisions. Wall Street Zen Downgrades Tenet Healthcare to Buy

Tenet Healthcare Company Profile

Tenet Healthcare Corporation NYSE: THC is a diversified American healthcare services company that owns and operates acute care hospitals and a broad range of outpatient facilities. Its portfolio includes general acute-care hospitals, specialty hospitals, ambulatory surgery centers, urgent care and diagnostic imaging centers, and other ancillary service locations. Tenet's operations are oriented around delivering inpatient and outpatient clinical care across multiple medical specialties, with an emphasis on surgical services, emergency care, and advanced diagnostics.

In addition to facility-based care, Tenet provides integrated services designed to support clinical operations and improve patient access and care coordination.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source